Current stock page

Stock Analysis

Exelixis, Inc. (EXEL) Stock Analysis

Exelixis, Inc. (EXEL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

EXEL Stock Analysis Summary

Exelixis, Inc. (EXEL) currently has an AIQ Score of 82/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Quality is the weakest current factor at 75/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

EXEL at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$69.00
AIQ Score82/100
Overall ViewVery Bullish
Technical Analysis ConsensusBuy
Market Cap$17.03B
P/E Ratio (TTM)20
Forward P/E—
EPS (Q3 FY2026)$0.88
Revenue (Q3 FY2026)$658.7M
Dividend Yield (TTM)0.00%
Beta0.61
Volume1.52M
52-week range$39.71-$73.69
RSI 1458.61
50-Day SMA$62.29
200-Day SMA$52.24
Analyst Price Target$58.67
Next EarningsFeb 9, 2027
As of Nov 13, 2026 · Market close

EXELExelixis, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

Very BullishEdge 10/10
$69.00−$0.84 (−1.20%)

Latest quote

  • Momentum
    91
  • Value
    79
  • Quality
    75
  • Risk resilience
    77
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

EXEL Stock Analysis Summary

Exelixis, Inc. (EXEL) currently has an AIQ Score of 82/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Quality is the weakest current factor at 75/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Very Bullish

In a very bullish regime, EXEL has AIQ Score of 82/100 with Momentum base of 91/100 and fading Quality at 75/100. Wait for component alignment before adding exposure.

Healthcare · -1.20% stock move · EXEL classified in Biotechnology.

Current Evidence

Very BullishEXEL is in a very bullish AIQ regime; Momentum is the strongest visible factor at 91/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is EXEL Bullish or Bearish Right Now?

EXEL currently has a very bullish overall setup. Momentum is the strongest factor at 91/100, while Quality is weakest at 75/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 75/100.
  • - Momentum is constructive at 91/100.
  • - Risk Resilience is supportive at 77/100.
  • - Price is +10.78% above its 50-day SMA.
  • - Technical consensus has more buy votes than sell votes (27 vs 12).
Bear Case
  • - Analyst target implies -14.98% downside from the latest quote.

Current Consensus

EXEL's Technical Analysis Consensus is currently Buy, with 27 buy, 7 neutral, and 12 sell votes. EXEL's 14-day RSI is 58.61, which places the stock in a constructive momentum range. EXEL's beta is 0.61, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in EXEL?

The largest recent change in EXEL is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-2.0
Quality
+0.0
Risk
+0.0

What Would Change the EXEL Outlook?

The current very bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

EXEL Decision Framework

Public evidence layers, setup checks, and risk context for Exelixis, Inc..

Exelixis, Inc. (EXEL) Stock Analysis

Exelixis, Inc. has an AIQ Score of 82/100 in a Very Bullish regime. Momentum is strongest at 91/100. Beta is 0.61, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextEXEL is in a Very Bullish AIQ regime with score 82/100.
Signal ConflictThe primary conflict is that momentum leads at 91/100 while quality lags at 75/100.
Factor EvidenceMomentum 91/100 · Value 79/100 · Quality 75/100 · Risk 77/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 91/100.

TimingPass

Momentum is 91/100 and RSI (14) is 58.6.

Regime fitPass

EXEL is in a Very Bullish regime at 82/100.

Risk controlPass

Risk factor is 77/100 with beta 0.61 and annual volatility 33.9%.

ConflictPass

Current conflict: momentum leads at 91/100 while quality lags at 75/100.

AIQ Score
82/100
Price
$69.00
Beta
0.61
RSI (14)
58.6

EXEL Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

EXEL Fundamentals

EXEL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$658.7M
Net income
$218.1M
Free cash flow
$277.47M
View full EXEL fundamental analysis

EXEL Technical Analysis

EXEL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Buy
RSI 14
58.61
Price vs SMA-50
+10.78%
View full EXEL technical analysis

EXEL Stock Catalysts

Track EXEL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 9, 2027
Analyst target
$58.67
News items
5
View EXEL earnings and stock catalysts

EXEL Dividend Analysis

EXEL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View EXEL dividend history and analysis

EXEL Financial Data

EXEL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$658.7M
EPS
$0.88
Periods
8
View EXEL financials

EXEL Risk Analysis

EXEL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.61
Risk score
77/100
1Y volatility
33.90%
View EXEL risk analysis

EXEL Stock News

EXEL stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read EXEL stock news

EXEL vs Biotechnology Peers

Current peer cohort: EXEL · FTRE · GMAB · HALO · HRMY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
EXEL
Current stock
82/10079/10091/10077/1001.533.90%Current
FTRE
Fortrea Holdings Inc.
75/10093/10088/10041/1001.2967.32%EXEL vs FTRE
GMAB
Genmab A/S
77/10071/10094/10058/1001.2945.85%EXEL vs GMAB
HALO
Halozyme Therapeutics, Inc.
78/10076/10084/10063/1000.9541.04%EXEL vs HALO
HRMY
Harmony Biosciences Holdings, Inc.
73/10089/10066/10063/1000.0740.59%EXEL vs HRMY
Pairwise Compare links: FTRE · GMAB · HALO · HRMYEXEL vs FTREEXEL vs GMABEXEL vs HALOEXEL vs HRMYCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a EXEL stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for EXEL: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
20
As of Nov 13, 2026
Revenue growth
10.19%
Gross margin
96.26%
Current debt / equity
0.09
Latest quarterly evidence

Latest period Oct 2, 2026.

Review fundamentals
Quarter revenue
$658.7M
Quarter net income
$218.1M
Quarter free cash flow
$277.47M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
58.61
MACD
2.5

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
77/100
Beta
0.61
Annual volatility
33.90%
Max drawdown
-12.59%

EXEL Stock FAQ

What is EXEL stock price today?

Exelixis, Inc.'s current stock price is $69.00. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is EXEL bullish or bearish right now?

EXEL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is EXEL's market cap?

EXEL's market cap is $17.03B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is EXEL's current P/E ratio?

EXEL's current P/E ratio is 20 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is EXEL's RSI?

EXEL's 14-day RSI is 58.61 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is EXEL above its 50-day and 200-day moving averages?

EXEL is 10.78% from its 50-day SMA and 32.07% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is EXEL's next earnings date?

EXEL's next earnings date is currently listed as Feb 9, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does EXEL pay a dividend?

EXEL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.